{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Age-related+Macular+Degeneration",
    "query": {
      "condition": "Neovascular Age-related Macular Degeneration"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 307,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Age-related+Macular+Degeneration&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:15:32.132Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03066258",
      "title": "Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RGX-314",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-03-29",
      "completion_date": "2021-06-17",
      "has_results": true,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 8,
      "location_summary": "Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066258"
    },
    {
      "nct_id": "NCT05989126",
      "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "aflibercept 8 mg PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2024-04-15",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05989126"
    },
    {
      "nct_id": "NCT01682382",
      "title": "Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration",
        "Choroidal Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sequenom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2012-08",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "Encinitas, California",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682382"
    },
    {
      "nct_id": "NCT01650948",
      "title": "Genetic Load and Phenotype in Aggressive AMD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RetnaGene AMD LDT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sequenom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Lexington, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01650948"
    },
    {
      "nct_id": "NCT05037396",
      "title": "Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Brolucizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 9457,
      "start_date": "2020-03-05",
      "completion_date": "2020-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037396"
    },
    {
      "nct_id": "NCT01013376",
      "title": "A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MC-1101",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MacuCLEAR, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2009-08",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2009-11-13",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01013376"
    },
    {
      "nct_id": "NCT02571972",
      "title": "Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Macular Degeneration",
        "Age-related Macular Degeneration",
        "Diabetic Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Dorzolamide-timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-02-01",
      "completion_date": "2015-12-20",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02571972"
    },
    {
      "nct_id": "NCT02307682",
      "title": "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Brolucizumab ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1775,
      "start_date": "2014-12-08",
      "completion_date": "2018-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307682"
    },
    {
      "nct_id": "NCT00729846",
      "title": "Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Choroidal Neovascularization",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "verteporfin photodynamic therapy reduced fluence",
          "type": "DEVICE"
        },
        {
          "name": "verteporfin photodynamic therapy standardfluence",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "California Retina Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2006-05",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2016-04-20",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 2,
      "location_summary": "Bakersfield, California • Santa Barbara, California",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729846"
    },
    {
      "nct_id": "NCT01089517",
      "title": "A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "E10030 plus Lucentis",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 449,
      "start_date": "2010-03",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-06-10T18:15:32.132Z",
      "location_count": 1,
      "location_summary": "West Columbia, South Carolina",
      "locations": [
        {
          "city": "West Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01089517"
    }
  ]
}